NCCN Expands Pediatric Cancer Guidelines with First-Ever Ewing Sarcoma Protocol
Event summary
- NCCN published first-ever guidelines for Pediatric Bone Sarcoma on October 1, 2026, focusing on Ewing sarcoma treatment.
- Guidelines developed by panel including 2,000+ experts from 34 NCCN Member Institutions and patient advocates.
- 5-year survival rate for early-stage Ewing sarcoma is 81%, dropping to 41% for metastatic cases.
- NCCN has added six pediatric cancer guidelines to its library in the past few years.
- Guidelines available for free at NCCN.org and via the Virtual Library of NCCN Guidelines App.
The big picture
The addition of Pediatric Bone Sarcoma guidelines to NCCN's library underscores the growing focus on specialized, evidence-based protocols for rare pediatric cancers. This move aligns with broader industry trends toward precision medicine and patient-centered care, particularly in oncology. The guidelines aim to standardize treatment approaches, potentially reducing variability in care and improving outcomes for a cancer type that affects approximately 200-300 children and adolescents annually in the U.S.
What we're watching
- Clinical Trial Impact
- How the new guidelines will influence enrollment and outcomes in Ewing sarcoma clinical trials.
- Risk Stratification
- Whether recent advances in risk stratification will translate to improved treatment outcomes.
- Pediatric Oncology Expansion
- The pace at which NCCN will add additional pediatric cancer guidelines to its library.
Related topics